- NEWS AND VIEWS
Super-potent opioids could be safer-than-expected alternatives to conventional painkillers
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
doi: https://doi.org/10.1038/d41586-026-00806-3
References
Darcq, E. & Kieffer, B. L. Nature Rev. Neurosci. 19, 499–514 (2018).
Mathis, V. P., Ehrlich, A. T. & Darcq, E. Nature Rev. Neurosci. 26, 778–797 (2025).
Gomez, J. L. et al. Nature https://doi.org/10.1038/s41586-026-10299-9 (2026).
Kieffer, B. L. & Evans, C. J. Cell 108, 587–590 (2002).
Manglik, A. et al. Nature 537, 185–190 (2016).
Stahl, E. L. et al. Nature 650, 500–508 (2026).
Ehrlich, A. T., Kieffer, B. L. & Darcq, E. Expert Opin. Ther. Targets 23, 315–326 (2019).
United Nations Office on Drugs and Crime. World Drug Report 2025 (UNODC, 2025).
Ujváry, I. et al. ACS Chem. Neurosci. 12, 1072–1092 (2021).
Koch, T. & Höllt, V. Pharmacol. Ther. 117, 199–206 (2008).
Volkow, N. D. & Blanco, C. Mol. Psychiatry 26, 218–233 (2021).
Competing Interests
The authors declare no competing interests.
Read the paper: Opiod receptorA μ-opioid receptor superagonist analgesic with minimal adverse effects
Dogma-defying signalling through G proteins could lead to better pain relief
Designer cannabinoids could be the key to pain relief without adverse effects